C:NYSECitigroup, Inc. Analysis
Data as of 2026-06-11 - not real-time
$133.38
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Citigroup’s stock is trading at $133.38, comfortably above its 20‑day (127.60), 50‑day (126.64) and 200‑day (111.94) moving averages, while the RSI sits at 60.8 and the MACD histogram is positive, signaling a bullish technical backdrop. Volume is on the rise, support sits near $119.76 and resistance near $137.12, and the 30‑day volatility of ~26% combined with a beta of 1.42 suggests the share will continue to move sharply with the market. On the fundamentals side, revenue grew 16% YoY to $78.7 B, operating margin is a healthy 34% and forward EPS of 12.53 points to a forward P/E of 10.6, well below the industry average of 16.5, indicating the stock is undervalued. However, operating cash flow is negative (-$30.8 B) and free cash flow is flat, raising questions about the sustainability of the 1.8% dividend despite a modest payout ratio of 29%.
Recent news adds momentum: a $30 B share‑buyback announced at Investor Day, a new private‑credit partnership with BlackRock, and a strategic push into tokenized securities are drawing investor attention, while analysts collectively rate the stock as a “Buy.” The combination of bullish technicals, attractive valuation multiples, and strategic growth initiatives supports a positive near‑term outlook, though the cash‑flow weakness and heightened regulatory exposure keep risk considerations in play.
Recent news adds momentum: a $30 B share‑buyback announced at Investor Day, a new private‑credit partnership with BlackRock, and a strategic push into tokenized securities are drawing investor attention, while analysts collectively rate the stock as a “Buy.” The combination of bullish technicals, attractive valuation multiples, and strategic growth initiatives supports a positive near‑term outlook, though the cash‑flow weakness and heightened regulatory exposure keep risk considerations in play.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical indicators and price above key moving averages
- Positive catalyst from $30 B buyback and tokenization strategy
- Undervaluation relative to industry P/E
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong earnings growth and improving forward EPS
- Dividend yield provides modest income
- Operating cash‑flow weakness and regulatory headwinds
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic diversification into tokenized securities and private credit
- Sustained undervaluation with attractive forward multiples
- Long‑term dividend and potential for continued share repurchases
Key Metrics & Analysis
Financial Health
Revenue Growth15.90%
Profit Margin20.36%
P/E Ratio16.5
ROE7.65%
ROA0.61%
P/B Ratio1.2
Op. Cash Flow$-30797000704
Industry P/E16.5
Technical Analysis
TrendBullish
RSI60.8
Support$119.76
Resistance$137.12
MA 20$127.60
MA 50$126.64
MA 200$111.94
MACDBullish
VolumeIncreasing
Fear & Greed Index84.55
Valuation
Target Price$146.93
Upside/Downside10.16%
GradeUndervalued
TypeBlend
Dividend Yield1.80%
Risk Assessment
Beta1.42
Volatility25.99%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.